Globicatella sanguinis is a rare, gram-positive bacterium that has been quietly causing human infections since at least the early 1990s, though it spent years hiding behind the identities of better-known organisms. Laboratories routinely misidentify it as a streptococcus or enterococcus, and that mistake carries real clinical consequences: the antibiotic most commonly used to treat the bugs it mimics performs poorly against it. With fewer than 60 documented cases in the medical literature, G. sanguinis remains an emerging pathogen whose true frequency is almost certainly underestimated.
How the Organism Was Discovered and Classified
The genus Globicatella was first proposed in 1992 after researchers performed phylogenetic analysis on a group of gram-positive, catalase-negative cocci isolated from human clinical specimens. These bacteria did not fit neatly into any existing genus. 16S rRNA sequencing showed they represented a previously unknown evolutionary lineage within the low-G+C gram-positive bacteria, and the name Globicatella sanguis (later corrected to G. sanguinis) was formally proposed.1PubMed. Globicatella sanguis gen.nov., sp.nov., a new gram-positive catalase-negative bacterium from human sources Before that, clinical isolates of this organism had been floating around in laboratories labeled as Streptococcus uberis or “S. uberis-like” strains, purely because their biochemical profiles looked similar enough to fool standard identification methods.2PubMed. DNA relatedness, phenotypic characteristics, and antimicrobial susceptibilities of Globicatella sanguinis strains
DNA-DNA relatedness testing later confirmed how distant G. sanguinis actually is from the organisms it resembles. Relatedness to Aerococcus viridans, Enterococcus avium, and Streptococcus uberis was less than 18%, putting Globicatella on its own branch entirely.2PubMed. DNA relatedness, phenotypic characteristics, and antimicrobial susceptibilities of Globicatella sanguinis strains That degree of genetic separation is enormous. For context, organisms within the same species typically share well above 70% DNA-DNA relatedness. G. sanguinis is as genetically remote from the streptococci it gets mistaken for as humans are from many other mammals.
The Misidentification Problem
If G. sanguinis were easy to spot in a clinical lab, it would likely have been recognized as a pathogen much sooner. The trouble is that commercial phenotypic identification systems, the workhorse tools most hospital microbiology labs rely on, consistently fail to distinguish it from streptococci and enterococci. One study tested 15 strains of G. sanguinis against four different commercial identification panels. The results included misidentification as aerococci, Streptococcus mutans, and enterococci, or no identification at all.3Open Forum Infectious Diseases. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease A broader literature review of case reports confirmed the pattern: conventional laboratory methods are insufficient for definitive identification, and systems like Vitek2, API, and Phoenix frequently return incorrect results.4PubMed Central. Globicatella sanguinis—A Literature Review of Case Reports
The most reliable identification methods are 16S rRNA gene sequencing and MALDI-TOF mass spectrometry, though the latter only works if the reference database includes Globicatella. Not all databases do. In a review of 51 cases, confirmation was achieved through DNA sequencing in 28 patients. Blood cultures identified the organism in 12 patients, cerebrospinal fluid cultures in 6, and urine culture in 1.4PubMed Central. Globicatella sanguinis—A Literature Review of Case Reports The practical implication is that clinicians and microbiologists need to think of G. sanguinis when they encounter gram-positive cocci that look like viridans group streptococci but show an unusual antibiotic susceptibility pattern, particularly elevated resistance to cephalosporins. That antibiotic quirk is often the first red flag.
Who Gets Infected
G. sanguinis infections are not randomly distributed. The available data, drawn from a small pool of documented cases, paint a fairly consistent picture of who is at risk. In a review of 37 known cases, about 83% of patients were female, and roughly 89% were at the extremes of age, meaning either younger than five or older than 65.5PubMed Central. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease A later and larger review of 51 patients showed a similar female predominance, with 30 women, 15 men, and 6 patients whose sex was not recorded.4PubMed Central. Globicatella sanguinis—A Literature Review of Case Reports
In more than two-thirds of cases, no clear source of infection can be identified. When a cause is traceable, common precipitants include surgical procedures or other invasive interventions, trauma, cat bites, an immunocompromised state, and complications of pregnancy or childbirth.4PubMed Central. Globicatella sanguinis—A Literature Review of Case Reports The predominance of very young children and elderly adults suggests that immature or weakened immune defenses play a role, though the organism has also caused serious infection in at least one immunocompetent patient.
What Infections It Causes
Bacteremia, meaning the presence of bacteria in the bloodstream, is by far the most common presentation. Among the first 37 reported cases, 27 involved bacteremia. Five involved central nervous system infections, at least two of which followed neurosurgical procedures. Four patients had urinary tract infections, and one had an orthopedic infection, the first bone infection attributed to this organism.3Open Forum Infectious Diseases. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease Endocarditis, though rare, has also been reported, and clinicians have noted that when G. sanguinis does cause infection of the heart valves, the course tends to be subacute rather than fulminant, following a pattern similar to infective endocarditis caused by viridans streptococci.6IDCases. Infective endocarditis following urinary tract infection caused by Globicatella sanguinis
Meningitis is the central nervous system infection most associated with G. sanguinis, and it has been reported both in community-acquired settings and in association with neurosurgical hardware. One documented case involved a 36-year-old man who developed meningitis linked to a ventriculoperitoneal shunt.7IP Indian Journal of Neurosciences. Ventriculoperitoneal shunt associated meningitis caused by Globicatella sanguinis: Review of an emerging human pathogen The connection to implanted devices and surgical sites fits the broader pattern: this organism appears to exploit breaches in the body’s physical barriers rather than overwhelming intact defenses.
The Antibiotic Pattern That Matters Most
Here is where misidentification becomes genuinely dangerous. When a lab tells a clinician they are dealing with viridans group streptococci, the go-to empiric therapy often includes a cephalosporin like ceftriaxone. For most viridans streptococci, this is a perfectly reasonable choice. For G. sanguinis, it is a poor one. The organism typically shows elevated resistance to cephalosporins while remaining quite susceptible to penicillin, a pattern that is essentially the reverse of what clinicians expect from viridans streptococci.3Open Forum Infectious Diseases. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease
The largest susceptibility survey of G. sanguinis strains found that the concentration of cefotaxime (a close relative of ceftriaxone) needed to inhibit half of tested isolates was 1 µg/mL, and the concentration needed to inhibit 90% was 4 µg/mL. For penicillin, those figures were dramatically lower at 0.06 µg/mL and 0.12 µg/mL respectively.5PubMed Central. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease In practical terms, penicillin works well against this organism while cephalosporins may not reach adequate tissue concentrations. Amoxicillin also performs well, as do chloramphenicol and levofloxacin. On the other hand, meropenem, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole all show elevated resistance.8Open Forum Infectious Diseases. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease Vancomycin resistance has not been reported, making it a reliable fallback in severe infections where the diagnosis remains uncertain.
A complicating factor is that no official interpretive guidelines exist for this organism. The Clinical and Laboratory Standards Institute (CLSI) has not published breakpoints for Globicatella, so laboratories that do manage to identify it correctly are encouraged to report raw minimum inhibitory concentration values rather than simplified “susceptible/intermediate/resistant” categories.8Open Forum Infectious Diseases. Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease That places the interpretive burden on the treating clinician, who may have limited experience with this organism. The bottom line for treatment, based on the available evidence, is that penicillin or amoxicillin should be considered first-line rather than cephalosporins whenever G. sanguinis is identified or strongly suspected.
Persistence in Catheter Biofilms
Beyond acute infections, G. sanguinis has been found living within polymicrobial biofilms on urethral catheters. Using a combination of 16S rDNA sequencing and proteomic analysis, researchers identified G. sanguinis coexisting with gram-negative uropathogens in catheter biofilm communities. Longitudinal sampling of biofilms from serially replaced catheters showed that G. sanguinis persisted in the urinary tract of a patient across multiple catheter changes, surviving alongside other organisms in what amounts to a cooperative microbial community.9PubMed Central. Aerococcus urinae and Globicatella sanguinis Persist in Polymicrobial Urethral Catheter Biofilms Examined in Longitudinal Profiles at the Proteomic Level
Biofilm formation matters because bacteria embedded in biofilms are far more resistant to both antibiotics and the immune system than their free-floating counterparts. This finding may partially explain why G. sanguinis can establish persistent urinary tract infections in catheterized patients, a population that overlaps heavily with the elderly and surgically compromised individuals who make up most documented cases. It also means that catheter removal or replacement is likely a key part of clearing the infection, not just antibiotics alone.
The Other Globicatella Species
The genus Globicatella contains only two formally described species. G. sulfidifaciens was identified from purulent infections in domestic animals and is biochemically and phenotypically distinct from G. sanguinis, though it shares the same genus.10PubMed. Globicatella sulfidifaciens sp. nov., isolated from purulent infections in domestic animals As of the most recent literature, G. sulfidifaciens has not been linked to any human infection. G. sanguinis remains the only confirmed human pathogen in the genus.11Emerging Infectious Diseases. Soft Tissue Infection of Immunocompetent Man with Cat-Derived Globicatella Species
That neat two-species picture is already being complicated, though. A case report from the United Kingdom described extensive soft tissue infection and tenosynovitis in an immunocompetent man who had been bitten by a stray domestic cat. The organism recovered from the wound represented a novel, as-yet-unnamed Globicatella species distinct from both G. sanguinis and G. sulfidifaciens.12PubMed Central. Soft Tissue Infection of Immunocompetent Man with Cat-Derived Globicatella Species Two things stand out about this case. First, the patient was immunocompetent, lacking the typical risk factors seen in G. sanguinis infections. Second, the source was clearly zoonotic, transmitted directly from a cat. This raises the possibility that animal reservoirs harbor additional Globicatella species capable of causing human disease, and that the genus may be more diverse than current databases reflect.
Phenotypic Features That Help With Identification
While molecular methods are the gold standard for identifying G. sanguinis, not every laboratory has ready access to sequencing or an up-to-date MALDI-TOF database. A detailed biochemical profile compiled from 28 strains offers some phenotypic clues. The organism is positive for the bile esculin test in all cases, grows at 45°C in about 96% of strains, shows a variable reaction for pyrrolidonylarylamidase production (about 75% positive), produces acid from arabinose in roughly 45% of strains, and does not hydrolyze starch.2PubMed. DNA relatedness, phenotypic characteristics, and antimicrobial susceptibilities of Globicatella sanguinis strains
In practice, a microbiologist facing a catalase-negative gram-positive coccus that looks like viridans streptococci but shows the unusual combination of a positive bile esculin reaction and cephalosporin resistance should have G. sanguinis on their short list. That combination is unusual enough to serve as a clinical flag even before molecular results come back. Sending the isolate for 16S rRNA sequencing remains the definitive step, but the biochemical profile can at least prompt a clinician to avoid cephalosporins while awaiting confirmation.
Why the True Infection Rate Is Almost Certainly Higher
Fifty-one documented cases over roughly three decades of reporting is a vanishingly small number. But the case count is shaped by the diagnostic tools used to find the organism, not just by its actual frequency. When commercial identification systems consistently return “viridans streptococci” or “enterococcus” for what is really G. sanguinis, the true pathogen never enters the medical record. Patients get treated empirically, sometimes with the wrong drug, and the infection either resolves on its own, responds to a broad-spectrum backup antibiotic, or causes complications attributed to the misidentified organism. None of those scenarios generate a G. sanguinis case report.
The increasing adoption of MALDI-TOF mass spectrometry in clinical labs worldwide, and the gradual expansion of its reference databases to include uncommon organisms, is likely to change this. As more laboratories can identify Globicatella without resorting to specialized sequencing, the reported case count will probably rise, not because infections are becoming more common, but because they are finally being correctly named. The trend is already visible in the literature: case reports have accelerated in recent years, clustering around institutions with access to molecular identification tools. Whether G. sanguinis will eventually be recognized as a genuinely common low-virulence pathogen, in the way Aerococcus urinae went from obscurity to a recognized cause of urinary tract infections in elderly men, remains to be seen. But the trajectory is pointing in that direction.